Tag: Ablative Solutions
Ablative Solutions announces publication of data from the Peregrine post-market study
Ablative Solutions has announced that positive six-month results from the Peregrine post-market study demonstrating the safety and efficacy of the company’s CE-marked Peregrine System infusion...
TARGET BP I trial enrols its first patient
The first patient has been randomised in the TARGET BP I trial at the Piedmont Heart Institute in Atlanta, USA, to investigate the use...
Unique therapeutic approach to treating uncontrolled hypertension receives US$77 million financing
Ablative Solutions has announced the first close of its US$77 million Series D funding round. The round was led by new investor Glide Healthcare,...
